Growth factor receptor/steroid receptor cross talk in trastuzumab-treated breast cancer

Dual regulation of Myc by Abl

(2013) V J Sanchez-Arévalo Lobo et al.   ONCOGENE

Antagonism between FOXO and MYC Regulates Cellular Powerhouse

(2013) Barrie Peck et al.   Frontiers in Oncology

An open-label study of lapatinib in women with HER-2-negative early breast cancer: the lapatinib pre-surgical study (LPS study)

(2012) R. C. Coombes et al.   ANNALS OF ONCOLOGY

Therapeutic implications of estrogen receptor signaling in HER2-positive breast cancers

(2012) Rita Nahta et al.   BREAST CANCER RESEARCH AND TREATMENT

Trastuzumab-Resistant Cells Rely on a HER2-PI3K-FoxO-Survivin Axis and Are Sensitive to PI3K Inhibitors

(2012) A. Chakrabarty et al.   CANCER RESEARCH

Preoperative Chemotherapy Plus Trastuzumab, Lapatinib, or Both in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer: Results of the Randomized Phase II CHER-LOB Study

(2012) Valentina Guarneri et al.   JOURNAL OF CLINICAL ONCOLOGY

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial

(2012) José Baselga et al.   LANCET

Junctional adhesion molecule-A is co-expressed with HER2 in breast tumors and acts as a novel regulator of HER2 protein degradation and signaling

(2012) K Brennan et al.   ONCOGENE

Metastatic Progression with Resistance to Aromatase Inhibitors Is Driven by the Steroid Receptor Coactivator SRC-1

(2011) J. McBryan et al.   CANCER RESEARCH

C-MYCAlterations and Association With Patient Outcome in Early-Stage HER2-Positive Breast Cancer From the North Central Cancer Treatment Group N9831 Adjuvant Trastuzumab Trial

(2011) Edith A. Perez et al.   JOURNAL OF CLINICAL ONCOLOGY

Mechanisms of Endocrine Resistance in Breast Cancer

(2010) C. Kent Osborne et al.   Annual Review of Medicine

Lapatinib Restores Hormone Sensitivity with Differential Effects on Estrogen Receptor Signaling in Cell Models of Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer with Acquired Endocrine Resistance

(2010) A. F. Leary et al.   CLINICAL CANCER RESEARCH

Ligand-Independent HER2/HER3/PI3K Complex Is Disrupted by Trastuzumab and Is Effectively Inhibited by the PI3K Inhibitor GDC-0941

(2009) Teemu T. Junttila et al.   CANCER CELL

Trastuzumab Reverses Letrozole Resistance and Amplifies the Sensitivity of Breast Cancer Cells to Estrogen

(2009) Gauri Sabnis et al.   CANCER RESEARCH

The Role of miR-206 in the Epidermal Growth Factor (EGF) Induced Repression of Estrogen Receptor-α (ERα) Signaling and a Luminal Phenotype in MCF-7 Breast Cancer Cells

(2009) Brian D. Adams et al.   MOLECULAR ENDOCRINOLOGY

Tamoxifen Resistance in Breast Tumors Is Driven by Growth Factor Receptor Signaling with Repression of Classic Estrogen Receptor Genomic Function

(2008) S. Massarweh et al.   CANCER RESEARCH

Acquired Resistance to Small Molecule ErbB2 Tyrosine Kinase Inhibitors

(2008) F. L. Chen et al.   CLINICAL CANCER RESEARCH

p300 provides a corepressor function by cooperating with YY1 and HDAC3 to repress c-Myc

(2008) N Sankar et al.   ONCOGENE